Yesterday I reported that Onyx Pharmaceuticals had temporarily delayed their drug application with the FDA for the new and highly anticipated anti-myeloma drug, carfilzomib.In the article, I passed along an e-mail I received from the company's Director of Corporate Communications & Investor Relations, Lori Murray.I was able to reach Lori by phone later in the
I just heard back from Onyx Pharmaceuticals' Director of Communications, Lori Murray, with an answer to yesterday's question from our reader in India:Hi Pat, We have a Phase 3 trial in Europe/Eastern Europe evaluating CFZ in relapsed/refractory to support a European filing. Unfortunately, we don’t have anything currently enrolling in India in the relapsed/refractory setting.
Thoughts About My Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Dr. Michael Kauffman At ASCO
I started an article about carfilzomib last Tuesday this way: The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib:"Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask."Well, you just read my interview with Dr. Michael Kauffman,
As promised, here is Part One of my three part series about last Friday's interview with Dr. Michael Kauffman, Chief Medical Officer/for Onyx Pharmaceuticals, maker of the new proteasome inhibitor, carfilzomib.First, here is what Google has to say about Dr. Kauffman:Director, CombinatoRx, Inc. CMO, Onyx PharmaceuticalsBoston , MA Sector: HEALTHCARE / Biotechnology 46 Years Old